Although the role of NURR1 in breast cancer is not well-understood yet, this positive correlation with ERgroup and negative correlation with proliferation group indicates that NURR1’s expression can be used to predict the poor outcomes of LumA subtype cases and help to decide whether an aggressive or a moderate therapy is necessitated. Here, NR4A2 is linked to breast cancer.